Qian Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Qian Zhao has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
Ji Jiang
Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 1 Shuaifuyuan, Dongcheng District, Beijing 100730, China
12 shared publications- Pei Hu
Clinical Pharmacology Research Center
9 shared publications Huanhuan Wang
Clinical Pharmacology Research Center, Beijing Key Laboratory of Clinical PK and PD Investigation for Innovative Drugs, Peking Union Medical College Hospital Union Medical College and Chinese Academy of Medical Sciences Beijing China
5 shared publicationsCheng Cui
Clinical Pharmacology Research Center and State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
4 shared publicationsKai Dong
Clinical Research Center for Innovative Drugs, Tianjin Chase Sun Pharmaceutical Co., Ltd Tianjin China
3 shared publicationsNi Wu
Clinical Pharmacology Research Center, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation Innovative Drugs for Major Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
3 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Springer Nature in Scientific Reports
A systematic review and meta-analysis of immunosuppressive regimens and immune-related outcomes in adeno-associated virus-based gene therapy
Significant progress has been made in adeno-associated virus (AAV)-based gene therapy. However, host immune responses remain a major challenge to its widespread clinical application, making immunosuppressive regimens an important component of clinical management. We performed a systematic review and meta-analysis to characterize immunosuppressive regimens and immune-related outcomes in clinical AAV gene therapy. The primary outcomes were the proportions of humoral immune responses, gene therapy-associated uveitis (GTAU), elevated alanine aminotransferase (ALT), and elevated creatine kinase (CK). A total of 73 studies involving 1773 participants were included and categorized as ocular (n = 31), liver (n = 22), muscle (n = 12), or central nervous system (n = 8) according to the primary target organ. Primary subgroup analyses were restricted to studies in which immunosuppression was used prophylactically. The pooled proportions of humoral immune responses were 27.7%, 75.8%, 35.2%, and 42.6% for ocular-, liver-, muscle-, and central nervous system-directed AAV gene therapy, respectively. The pooled proportions of GTAU in ocular-directed studies, elevated ALT in liver-directed studies, elevated CK in muscle-directed studies, and elevated ALT in central nervous system-directed studies were 24.2%, 49.5%, 5.1%, and 16.5%, respectively. Statistically significant regimen-based subgroup differences were observed for GTAU in ocular-directed studies and for humoral immune responses in muscle-directed studies. However, the current evidence does not establish the superiority of any specific immunosuppressive regimen. These findings highlight variation in immune-related outcomes across target organs and the need for more clinical studies with standardized outcome reporting to better inform immunosuppressive strategies in AAV gene therapy.
- 1 October 2026
- Published by Springer Nature in Scientific Reports
Open AccessA systematic review and meta-analysis of immunosuppressive regimens and immune-related outcomes in adeno-associated virus-based gene therapy
Significant progress has been made in adeno-associated virus (AAV)-based gene therapy. However, host immune responses remain a major challenge to its widespread clinical application, making immunosuppressive regimens an important component of clinical management. We performed a systematic review and meta-analysis to characterize immunosuppressive regimens and immune-related outcomes in clinical AAV gene therapy. The primary outcomes were the proportions of humoral immune responses, gene therapy-associated uveitis (GTAU), elevated alanine aminotransferase (ALT), and elevated creatine kinase (CK). A total of 73 studies involving 1773 participants were included and categorized as ocular (n = 31), liver (n = 22), muscle (n = 12), or central nervous system (n = 8) according to the primary target organ. Primary subgroup analyses were restricted to studies in which immunosuppression was used prophylactically. The pooled proportions of humoral immune responses were 27.7%, 75.8%, 35.2%, and 42.6% for ocular-, liver-, muscle-, and central nervous system-directed AAV gene therapy, respectively. The pooled proportions of GTAU in ocular-directed studies, elevated ALT in liver-directed studies, elevated CK in muscle-directed studies, and elevated ALT in central nervous system-directed studies were 24.2%, 49.5%, 5.1%, and 16.5%, respectively. Statistically significant regimen-based subgroup differences were observed for GTAU in ocular-directed studies and for humoral immune responses in muscle-directed studies. However, the current evidence does not establish the superiority of any specific immunosuppressive regimen. These findings highlight variation in immune-related outcomes across target organs and the need for more clinical studies with standardized outcome reporting to better inform immunosuppressive strategies in AAV gene therapy.
- 30 March 2026
- Published by Springer Nature in Current Medical Science
- p. 1-20
Strategies for Evading Cellular Immunity Against Recombinant AAV Vectors in Gene Therapy
Over the past decade, adeno-associated virus (AAV) vectors have emerged as a powerful tool for in vivo gene transfer, owing to their diverse tissue tropisms, predominantly non-integrative property, and superior safety profile compared with other viral vectors. As of December 2025, ten gene therapies based on recombinant AAV (rAAV) vectors have been approved globally, primarily by the Food and Drug Administration (FDA) and/or the European Medicines Agency (EMA). However, seroprevalence surveys indicate that most individuals carry anti-AAV neutralizing antibodies (NAbs), and nearly 50% of healthy individuals exhibit detectable frequencies of circulating AAV capsid-specific CD8+ T cells and/or CD4+ T cells. Clinical studies suggest that immune responses mediated by cytotoxic T lymphocytes (CTLs) targeting transduced cells are a key factor limiting the long-term effectiveness of rAAV-mediated gene therapy. Herein, we summarize strategies to evade anti-rAAV cellular immunity, discussing their advantages and limitations in the context of the rAAV transduction process and mechanisms of cellular immune responses. Furthermore, we highlight key challenges in research on rAAV gene therapy immunogenicity, as well as emerging technologies with potential applications in this field.
- 30 March 2026
- Published by Springer Nature in Current Medical Science
- p. 1-20
Strategies for Evading Cellular Immunity Against Recombinant AAV Vectors in Gene Therapy
Over the past decade, adeno-associated virus (AAV) vectors have emerged as a powerful tool for in vivo gene transfer, owing to their diverse tissue tropisms, predominantly non-integrative property, and superior safety profile compared with other viral vectors. As of December 2025, ten gene therapies based on recombinant AAV (rAAV) vectors have been approved globally, primarily by the Food and Drug Administration (FDA) and/or the European Medicines Agency (EMA). However, seroprevalence surveys indicate that most individuals carry anti-AAV neutralizing antibodies (NAbs), and nearly 50% of healthy individuals exhibit detectable frequencies of circulating AAV capsid-specific CD8+ T cells and/or CD4+ T cells. Clinical studies suggest that immune responses mediated by cytotoxic T lymphocytes (CTLs) targeting transduced cells are a key factor limiting the long-term effectiveness of rAAV-mediated gene therapy. Herein, we summarize strategies to evade anti-rAAV cellular immunity, discussing their advantages and limitations in the context of the rAAV transduction process and mechanisms of cellular immune responses. Furthermore, we highlight key challenges in research on rAAV gene therapy immunogenicity, as well as emerging technologies with potential applications in this field.
- 8 January 2025
- Published by Wiley in Biomedical Chromatography
- Vol. 39 (2) , e6076
An Ultra‐Performance Liquid Chromatography–Tandem Mass Spectrometry Method for the Determination of Deoxycholic Acid and Application to a Pharmacokinetic Study in Human Plasma
Deoxycholic acid (DCA) injection is applied in treating moderate to severe submental bulge or facial fullness caused by excessive submental fat accumulation. Using ultra‐performance liquid chromatography–tandem mass spectrometry (UPLC–MS/MS) technology, which was swiftly, precisely, and reliably confirmed, DCA was determined in human plasma with low quantification limits of 56 ng/mL. We selected six healthy individual blank human plasma with low concentrations of endogenous DCA and mixed them to prepare standard curve samples. The samples were purified by the protein precipitation technique and then separated using a BEH C18 column (2.1 × 50 mm, 1.7 μm). Using multiple reaction monitoring (MRM) and electrospray ionization (ESI) sources operating in negative mode, the mass was identified and measured. The precursor‐to‐product ion transitions were observed at m/z 391.2− → 345.2− and m/z 395.2− → 349.2− for DCA and DCA‐d4 (isotope internal standard), respectively. This method was thoroughly validated, encompassing assessments of linearity, sensitivity, precision, selectivity, stability, matrix effect, accuracy, carryover, and recovery. In a word, the validation results demonstrated that this method exhibited sensitivity, accuracy, and reproducibility and could effectively be utilized for studying the pharmacokinetic properties of DCA in a randomized, parallel, controlled, Phase I clinical trial.
- 8 January 2025
- Published by Wiley in Biomedical Chromatography
- Vol. 39 (2) , e6076
An Ultra‐Performance Liquid Chromatography–Tandem Mass Spectrometry Method for the Determination of Deoxycholic Acid and Application to a Pharmacokinetic Study in Human Plasma
Deoxycholic acid (DCA) injection is applied in treating moderate to severe submental bulge or facial fullness caused by excessive submental fat accumulation. Using ultra‐performance liquid chromatography–tandem mass spectrometry (UPLC–MS/MS) technology, which was swiftly, precisely, and reliably confirmed, DCA was determined in human plasma with low quantification limits of 56 ng/mL. We selected six healthy individual blank human plasma with low concentrations of endogenous DCA and mixed them to prepare standard curve samples. The samples were purified by the protein precipitation technique and then separated using a BEH C18 column (2.1 × 50 mm, 1.7 μm). Using multiple reaction monitoring (MRM) and electrospray ionization (ESI) sources operating in negative mode, the mass was identified and measured. The precursor‐to‐product ion transitions were observed at m/z 391.2− → 345.2− and m/z 395.2− → 349.2− for DCA and DCA‐d4 (isotope internal standard), respectively. This method was thoroughly validated, encompassing assessments of linearity, sensitivity, precision, selectivity, stability, matrix effect, accuracy, carryover, and recovery. In a word, the validation results demonstrated that this method exhibited sensitivity, accuracy, and reproducibility and could effectively be utilized for studying the pharmacokinetic properties of DCA in a randomized, parallel, controlled, Phase I clinical trial.
- Open Access
Methodological Validation and Inter-Laboratory Comparison of Microneutralization Assay for Detecting Anti-AAV9 Neutralizing Antibody in Human
Anti-AAV neutralizing Abs (NAbs) titer is usually measured by cell-based microneutralization (MN) assay and is crucial for patient screening in AAV-based gene therapy clinical trials. However, achieving uniform operation and comparable results among different laboratories remains challenging. Here, we established a standardized MN assay for anti-AAV9 NAbs in human sera or plasma and transferred the method to the other two research teams. Then, we validated its parameters and tested a set of eight human samples in blind across all laboratories. The end-point titer, defined by a transduction inhibition of 50% (IC50), was calculated using curve-fit modelling. A mouse neutralizing monoclonal antibody in human negative serum was used for system quality control (QC), requiring inter-assay titer variation of <4-fold difference or geometric coefficient of variation (%GCV) of <50%. The assay demonstrated a sensitivity of 54 ng/mL and no cross-reactivity to 20 μg/mL anti-AAV8 MoAb. The intra-assay and inter-assay variation for the low positive QC were 7–35% and 22–41%, respectively. The titers of the blind samples showed excellent reproducibility within and among laboratories, with a %GCV of 18–59% and 23–46%, respectively. This study provides a commonly transferrable MN assay for evaluating anti-AAV9 NAbs in humans, supporting its application in clinical trials.
Open AccessMethodological Validation and Inter-Laboratory Comparison of Microneutralization Assay for Detecting Anti-AAV9 Neutralizing Antibody in Human
Anti-AAV neutralizing Abs (NAbs) titer is usually measured by cell-based microneutralization (MN) assay and is crucial for patient screening in AAV-based gene therapy clinical trials. However, achieving uniform operation and comparable results among different laboratories remains challenging. Here, we established a standardized MN assay for anti-AAV9 NAbs in human sera or plasma and transferred the method to the other two research teams. Then, we validated its parameters and tested a set of eight human samples in blind across all laboratories. The end-point titer, defined by a transduction inhibition of 50% (IC50), was calculated using curve-fit modelling. A mouse neutralizing monoclonal antibody in human negative serum was used for system quality control (QC), requiring inter-assay titer variation of <4-fold difference or geometric coefficient of variation (%GCV) of <50%. The assay demonstrated a sensitivity of 54 ng/mL and no cross-reactivity to 20 μg/mL anti-AAV8 MoAb. The intra-assay and inter-assay variation for the low positive QC were 7–35% and 22–41%, respectively. The titers of the blind samples showed excellent reproducibility within and among laboratories, with a %GCV of 18–59% and 23–46%, respectively. This study provides a commonly transferrable MN assay for evaluating anti-AAV9 NAbs in humans, supporting its application in clinical trials.
- 23 April 2022
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 88 (9) , 4111-4120
Fixed dosing of kukoamine B in sepsis patients: Results from population pharmacokinetic modelling and simulation
Aims To assess the appropriateness of the body weight or fixed dosing regimen, a population pharmacokinetic (PopPK) model of kukoamine B has been built in sepsis patients. Methods Plasma concentrations of kukoamine B and the covariates information were taken from 30 sepsis patients assigned into 0.06 mg/kg, 0.12 mg/kg and 0.24 mg/kg groups in a Phase IIa clinical trial. The PopPK model was built using a nonlinear mixed-effect (NLME) modelling approach. Based on the final model, PK profiles were respectively simulated 500 times applying the body weight and renal function information of 12 sepsis patients from the 0.24 mg/kg group on the body weight or the fixed dosing regimen. For each dosing regimen, PK profiles of 6000 virtual patients were obtained. Statistical analyses for C-max and C-min were performed. If the biases of C-max and C-min can all meet the criteria of +/- 15%, the fixed dosing regimen can substitute for the body weight dosing regimen. Results The PopPK model was successfully developed using the NLME approach. A bi-compartmental model was selected as the basic model. Renal function was identified as a statistically significant covariate of systemic clearance with the objective function value (OFV) decreasing 8.6, resulting in a 5.2% decrease in inter-individual variability (IIV) of systemic clearance. Body weight was not identified as a statistically significant covariate. Simulation results demonstrated two methods had a bias of 8.1% for C-max, and 8.6% for C-min. Furthermore, PK variability was lower on the fixed dosing regimen than the body weight regimen. Conclusions Based on the simulation results, a fixed dosing regimen was recommended in the subsequent clinical trials.
- 23 April 2022
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 88 (9) , 4111-4120
Fixed dosing of kukoamine B in sepsis patients: Results from population pharmacokinetic modelling and simulation
Aims To assess the appropriateness of the body weight or fixed dosing regimen, a population pharmacokinetic (PopPK) model of kukoamine B has been built in sepsis patients. Methods Plasma concentrations of kukoamine B and the covariates information were taken from 30 sepsis patients assigned into 0.06 mg/kg, 0.12 mg/kg and 0.24 mg/kg groups in a Phase IIa clinical trial. The PopPK model was built using a nonlinear mixed-effect (NLME) modelling approach. Based on the final model, PK profiles were respectively simulated 500 times applying the body weight and renal function information of 12 sepsis patients from the 0.24 mg/kg group on the body weight or the fixed dosing regimen. For each dosing regimen, PK profiles of 6000 virtual patients were obtained. Statistical analyses for C-max and C-min were performed. If the biases of C-max and C-min can all meet the criteria of +/- 15%, the fixed dosing regimen can substitute for the body weight dosing regimen. Results The PopPK model was successfully developed using the NLME approach. A bi-compartmental model was selected as the basic model. Renal function was identified as a statistically significant covariate of systemic clearance with the objective function value (OFV) decreasing 8.6, resulting in a 5.2% decrease in inter-individual variability (IIV) of systemic clearance. Body weight was not identified as a statistically significant covariate. Simulation results demonstrated two methods had a bias of 8.1% for C-max, and 8.6% for C-min. Furthermore, PK variability was lower on the fixed dosing regimen than the body weight regimen. Conclusions Based on the simulation results, a fixed dosing regimen was recommended in the subsequent clinical trials.
- Open Access
- 19 April 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Exposure-Response Modeling to Support Dosing Selection for Phase IIb Development of Kukoamine B in Sepsis Patients
Aim: Kukoamine B, a small molecule compound, is being developed for the treatment of sepsis in a Phase II clinical trial. The objective of this study was to optimize dosing selection for a Phase IIb clinical trial using an exposure-response model.Methods: Data of 34 sepsis patients from a Phase IIa clinical trial were used in the model: 10 sepsis patients from the placebo group and a total of 24 sepsis patients from the 0.06 mg/kg, 0.12 mg/kg, and 0.24 mg/kg drug groups. Exposure-response relationship was constructed to model the impact of the standard care therapy and area under curve (AUC) of kukoamine B to the disease biomarker (SOFA score). The model was evaluated by goodness of fit and visual predictive check. The simulation was performed 1,000 times based on the built model.Results: The data of the placebo and the drug groups were pooled and modeled by a nonlinear mixed-effect modeling approach in sepsis. A latent-variable approach in conjunction with an inhibitory indirect response model was used to link the standard care therapy effect and drug exposure to SOFA score. The maximum fraction of the standard care therapy was estimated to 0.792. The eliminate rate constant of the SOFA score was 0.263/day for the standard care therapy. The production rate of SOFA score (Kin) was estimated at 0.0569/day and the AUC at half the maximal drug effect (EAUC50) was estimated at 1,320 h*ng/mL. Model evaluation showed that the built model could well describe the observed SOFA score. Model-based simulations showed that the SOFA score on day 7 decreased to a plateau when AUC increased to 1,500 h*ng/mL.Conclusion: We built an exposure-response model characterizing the pharmacological effect of kukoamine B from the standard care therapy in sepsis patients. A dose regimen of 0.24 mg/kg was finally recommended for the Phase IIb clinical trial of kukoamine B based on modeling and simulation results.
- 19 April 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Open AccessExposure-Response Modeling to Support Dosing Selection for Phase IIb Development of Kukoamine B in Sepsis Patients
Aim: Kukoamine B, a small molecule compound, is being developed for the treatment of sepsis in a Phase II clinical trial. The objective of this study was to optimize dosing selection for a Phase IIb clinical trial using an exposure-response model.Methods: Data of 34 sepsis patients from a Phase IIa clinical trial were used in the model: 10 sepsis patients from the placebo group and a total of 24 sepsis patients from the 0.06 mg/kg, 0.12 mg/kg, and 0.24 mg/kg drug groups. Exposure-response relationship was constructed to model the impact of the standard care therapy and area under curve (AUC) of kukoamine B to the disease biomarker (SOFA score). The model was evaluated by goodness of fit and visual predictive check. The simulation was performed 1,000 times based on the built model.Results: The data of the placebo and the drug groups were pooled and modeled by a nonlinear mixed-effect modeling approach in sepsis. A latent-variable approach in conjunction with an inhibitory indirect response model was used to link the standard care therapy effect and drug exposure to SOFA score. The maximum fraction of the standard care therapy was estimated to 0.792. The eliminate rate constant of the SOFA score was 0.263/day for the standard care therapy. The production rate of SOFA score (Kin) was estimated at 0.0569/day and the AUC at half the maximal drug effect (EAUC50) was estimated at 1,320 h*ng/mL. Model evaluation showed that the built model could well describe the observed SOFA score. Model-based simulations showed that the SOFA score on day 7 decreased to a plateau when AUC increased to 1,500 h*ng/mL.Conclusion: We built an exposure-response model characterizing the pharmacological effect of kukoamine B from the standard care therapy in sepsis patients. A dose regimen of 0.24 mg/kg was finally recommended for the Phase IIb clinical trial of kukoamine B based on modeling and simulation results.
- 29 October 2020
- Published by Taylor & Francis in Bioanalysis
- Vol. 12 (22) , 1635-1646
Application of LC–MS/MS Method for Determination of Dihydroartemisin in Human Plasma in a Pharmacokinetic Study
Aim: Dihydroartemisinin (DHA) was also found therapeutic potential for the treatment of systemic lupus erythematosus (SLE). To assess the pharmacokinetic profile of DHA, the concentration of DHA in...
- 29 October 2020
- Published by Taylor & Francis in Bioanalysis
- Vol. 12 (22) , 1635-1646
Application of LC–MS/MS Method for Determination of Dihydroartemisin in Human Plasma in a Pharmacokinetic Study
Aim: Dihydroartemisinin (DHA) was also found therapeutic potential for the treatment of systemic lupus erythematosus (SLE). To assess the pharmacokinetic profile of DHA, the concentration of DHA in...
- 29 May 2020
- Published by Taylor & Francis in Bioanalysis
- Vol. 12 (9) , 583-596
A UHPLC–MS/MS Method to Determine FLZ Major Active Metabolites in Human Plasma: Application to a Pharmacokinetic Study
Aim: FLZ, a novel promising dopamine neuroprotective agent, is designed to treat Parkinson's disease. F7G and F21G are FLZ major active Phase II metabolites whose exposure are nearly 100-times high...
- 29 May 2020
- Published by Taylor & Francis in Bioanalysis
- Vol. 12 (9) , 583-596
A UHPLC–MS/MS Method to Determine FLZ Major Active Metabolites in Human Plasma: Application to a Pharmacokinetic Study
Aim: FLZ, a novel promising dopamine neuroprotective agent, is designed to treat Parkinson's disease. F7G and F21G are FLZ major active Phase II metabolites whose exposure are nearly 100-times high...
- 1 March 2020
- Published by Future Science Ltd in Bioanalysis
- Vol. 12 (6) , 367-378
UHPLC-MS/MS method to determine FP-208 in human plasma and its application to a pharmacokinetic study
Aim: FP-208 is a novel and effective small-molecule inhibitor blocking the mammalian target of rapamycin complex-1/mammalian target of rapamycin complex-2/PI3Ka. To investigate the pharmacokinetic profile of FP-208, a rapid and reliable analytical method was needed to be established to determine FP-208 in the plasma of patients with solid tumors. Materials & methods: FP208 was separated on a charged surface hybrid (CSH) C18 column (2.1 mm x 50 mm, 1.7 mu m) after the plasma samples were purified using a protein precipitation method. Detection was performed on an AB Sciex 5500 mass spectrometer in the positive electrospray ionization mode. The established method was validated according to the bioanalytical guidelines. Conclusion: For the first time, the developed and validated method was successfully applied in the first-in-human study for FP-208 in patients with solid tumors after oral administration (Number: CTR20180683).
- 1 March 2020
- Published by Future Science Ltd in Bioanalysis
- Vol. 12 (6) , 367-378
UHPLC-MS/MS method to determine FP-208 in human plasma and its application to a pharmacokinetic study
Aim: FP-208 is a novel and effective small-molecule inhibitor blocking the mammalian target of rapamycin complex-1/mammalian target of rapamycin complex-2/PI3Ka. To investigate the pharmacokinetic profile of FP-208, a rapid and reliable analytical method was needed to be established to determine FP-208 in the plasma of patients with solid tumors. Materials & methods: FP208 was separated on a charged surface hybrid (CSH) C18 column (2.1 mm x 50 mm, 1.7 mu m) after the plasma samples were purified using a protein precipitation method. Detection was performed on an AB Sciex 5500 mass spectrometer in the positive electrospray ionization mode. The established method was validated according to the bioanalytical guidelines. Conclusion: For the first time, the developed and validated method was successfully applied in the first-in-human study for FP-208 in patients with solid tumors after oral administration (Number: CTR20180683).